Wanbury Receives Australian TGA GMP Compliance Certificate for Tanuku Facility
Wanbury Ltd · Press Release · 30 Oct 2026, 6:32 pm
Wanbury Receives Australian TGA GMP Compliance Certificate for Tanuku Facility Wanbury Limited secured a Good Manufacturing Practice (GMP) compliance certificate from Australia's Therapeutic Goods Administration (TGA) for its Tanuku manufacturing facility in Andhra Pradesh. Issued on 28th Oct'26 following an inspection conducted on 8th–9th Jun'26, the certification is valid until 9th Dec'28. The approval covers six active pharmaceutical ingredients (APIs): Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid, and Paroxetine Hydrochloride Hemihydrate. The clearance enables TGA to issue GMP clearances to Australian sponsors, facilitating regulated supply into the Australian market.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. · 18 Nov 2026
- Clarifications on investor queries regarding recent announcement · 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates · 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. · 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. · 06 Nov 2026
- Financial Results as on 30th September, 2026 · 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 · 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
